2024-11-13 19:29
We are advised by Alphamab Oncology that journalists and other readers should disregard the news release, A Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Included in the Pilot Program for Optimizing the Review and Approval of Clinical Trials for Innovative Drugs, issued 13-Nov-2024 over PR Newswire.
source: Alphamab Oncology
樂本健【年度感謝祭】維柏健及natural Factors全線2件7折► 了解詳情
上一篇新聞︰2024-11-13 20:00 橫跨五大洲的七個團隊，創新驅動創業的明日領袖：麻省理工學院 MIT REAP Cohort 11 正式啟動
下一篇新聞︰2024-11-13 18:49 Move Well and Discover Your Destination with Westin Hotels & Resorts' Top Routes across Asia Pacific Excluding China
2024-11-13 20:10 NaoTrac Robot Pioneers Robotic Neurosurgery in Bolivia with Successful Brain Tumor Biopsies
2024-11-13 20:09 春金集團在2024年全球兒童論壇基準中排名前五
2024-11-13 20:00 Seven Teams Across 5 Continents Represent the Next Leaders in Innovation-Driven Entrepreneurship with the Launch of MIT REAP Cohort 11
2024-11-13 18:45 新華絲路：無錫市錫山區舉辦招商合作懇談會
2024-11-13 18:38 新華絲路：七年「香」約進博會 五糧液為繁榮未來貢獻「和美」力量
新聞
股票
期貨期權N
權證
ETF
A股
外匯黃金
加密貨幣
基金
MPF
